Reference health
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
30566-x/badge.svg){kind=icon}
1 of 32 checkable references need attention · checked 2026-07-23
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
marked retracted — notice via Crossref, record curated by Retraction Watch10.1016/j.ijantimicag.2020.105949
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
The 31 checked references that resolve
resolves10.1093/jac/dkg007
Early administration of oral oseltamivir increases the benefits of influenza treatment
resolves10.3851/IMP2128
Effect of Oseltamivir, Zanamivir or Oseltamivir– Zanamivir Combination Treatments on Transmission of Influenza in Households
resolves10.1016/j.chom.2020.05.008
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
resolves10.15252/emmm.201606413
IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment
resolves10.1038/s41586-020-2708-8
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
resolves10.1128/JVI.00985-20
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures
resolves10.1016/j.jhep.2014.07.022
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
resolves10.1016/j.jhep.2015.12.018
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
resolves10.1038/ng.2521
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
resolves10.1038/nature08309
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
resolves10.1038/nature08463
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
resolves10.1093/cid/ciaa638
Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples
resolves10.1007/s10096-020-03913-9
Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards
resolves10.1056/NEJMoa2035002
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
resolves10.1093/cid/ciaa410
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19
resolves10.1126/science.abc6027
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
resolves10.1126/science.abd4585
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
resolves10.1126/science.abd4570
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
resolves10.3851/IMP3362
Combination Antiviral Therapy with Lopinavir/Ritonavir, Arbidol and Interferon-α1b for COVID-19
resolves10.1016/S0140-6736(20)31042-4
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
resolves10.1016/S2213-2600(20)30511-7
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
resolves10.1016/S0140-6736(20)30566-3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
resolves10.1016/j.jcv.2020.104455
Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis
resolves10.1002/hep.510300319
Racial differences in responses to therapy with interferon in chronic hepatitis C
resolves10.1016/S1542-3565(04)00615-9
Interferon-Stimulated Gene Expression in Black and White Hepatitis C Patients During Peginterferon Alfa-2a Combination Therapy
resolves10.1183/23120541.00260-2020
D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review
resolves10.1016/j.thromres.2020.08.032
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
The 7 references without a DOI — listed, not checked
no DOI — not checkedDexamethasone in hospitalized patients with COVID-19—preliminary report
no DOI — not checkedSARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19
no DOI — not checkedA pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
no DOI — not checkedViral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study
no DOI — not checkedPeginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
no DOI — not checkedInterferon-α2b treatment for COVID-19
no DOI — not checkedRepurposed antiviral drugs for COVID-19—interim WHO Solidarity trial results
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s2213-2600(20)30566-x"><img src="https://citestamp.com/citestamped/10.1016/s2213-2600(20)30566-x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[30566-x/badge.svg)](https://citestamp.com/citestamped/10.1016/s2213-2600(20)30566-x)